Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (8431)	5/20/2003 1:08:09 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

a clear picture of how VEGF production sorts out among cancer types I do know that VEGF is overexpressed in stomach cancer as well as colon cancer. Pancreatic cancer seems more variable. When the dust settles, I'll bet they find a few dozen growth factors that are significantly overexpressed in various cancers. It's going to be quite a challenge to figure out what combinations of factors are critical for each different cancer type (and potentially stage). Note incidentally that there is also quite a bit of work on anti-VEGF in macular degeneration as well as cancer. For example, Eyetech recently announced a very significant partnership with Pfizer in this area. (Incidentally their drug, Macugen, was licensed from GILD). Also I think RNAI has a similar program. Peter